title: Prognostic influence of loss of blood group A antigen expression in pathologic stage I non-small-cell lung cancer.
abstract: BACKGROUND
  In the scientific literature, contradictory results has been published on the prognostic value of the loss of expression of blood group antigen A (BAA) in lung cancer. The objective of our study was to analyze this fact in our surgical series.
  
  
  METHODS
  In a multicenter study, 402 non-small-cell lung cancer (NSCLC) patients were included. All were classified as stage-I according to the last 2009-TNM classification. We analyzed the prognostic influence of the loss of expression of BAA in the 209 patients expressing blood group A or AB.
  
  
  RESULTS
  The 5-year cumulative survival was 73% for patients expressing BAA vs 53% for patients with loss of expression (P=.03). When patients were grouped into stages IA and IB, statistical significance was only observed in stage I-A (P=.038). When we analyzed the survival according to histologic type, those patients with adenocarcinoma and loss of expression of BAA had a lower survival rate that was statistically very significant (P=.003). The multivariate analysis showed that age, gender and expression of BAA were independent prognostic factors.
  
  
  CONCLUSIONS
  The loss of expression of blood group antigen A has a negative prognostic impact in stage I NSCLC, especially in patients with adenocarcinoma.
authors.affiliation: Sección de Cirugía Torácica, Complejo Hospitalario Universitario de Albacete, Albacete, España. pabl1150@separ.es
authors.forename: Pablo
authors.initials: P
authors.lastname: León-Atance
authors.forename: Nicolás
authors.initials: N
authors.lastname: Moreno-Mata
authors.forename: Federico
authors.initials: F
authors.lastname: González-Aragoneses
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Cañizares-Carretero
authors.forename: Enrique
authors.initials: E
authors.lastname: Poblet-Martínez
authors.forename: Marta
authors.initials: M
authors.lastname: Genovés-Crespo
authors.forename: María Dolores
authors.initials: MD
authors.lastname: García-Jiménez
authors.forename: Antonio Francisco
authors.initials: AF
authors.lastname: Honguero-Martínez
authors.forename: Carlos Alberto
authors.initials: CA
authors.lastname: Rombolá
authors.forename: Carlos María
authors.initials: CM
authors.lastname: Simón-Adiego
authors.forename: Rafael
authors.initials: R
authors.lastname: Peñalver-Pacual
authors.forename: Emilio
authors.initials: E
authors.lastname: Alvarez-Fernández
mesh_terms: D000017:ABO Blood-Group System / Q000378:metabolism*; D000230:Adenocarcinoma / Q000737:chemistry / Q000201:enzymology / Q000401:mortality / Q000473:pathology / Q000601:surgery; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry / Q000201:enzymology* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D002872:Chromosome Deletion; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics*; D019175:DNA Methylation; D005260:Female; D017353:Gene Deletion; D006801:Humans; D007124:Immunoenzyme Techniques; D008175:Lung Neoplasms / Q000737:chemistry / Q000201:enzymology* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D017350:N-Acetylgalactosaminyltransferases / Q000172:deficiency* / Q000235:genetics / Q000378:metabolism; D009363:Neoplasm Proteins / Q000172:deficiency* / Q000235:genetics / Q000378:metabolism; D009367:Neoplasm Staging; D011013:Pneumonectomy; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D000017:ABO Blood-Group System; D000951:Antigens, Neoplasm; D009363:Neoplasm Proteins; D017350:N-Acetylgalactosaminyltransferases; C003742:UDPgalactosamine-galactose acetylgalactosaminyltransferase